Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

UroGen Pharma (URGN) FCF Margin: 2017-2025

Historic FCF Margin for UroGen Pharma (URGN) over the last 6 years, with Sep 2025 value amounting to -154.13%.

  • UroGen Pharma's FCF Margin fell 4399.00% to -154.13% in Q3 2025 from the same period last year, while for Sep 2025 it was -143.11%, marking a year-over-year decrease of 3526.00%. This contributed to the annual value of -107.37% for FY2024, which is 1480.00% down from last year.
  • As of Q3 2025, UroGen Pharma's FCF Margin stood at -154.13%, which was up 6.62% from -165.05% recorded in Q2 2025.
  • In the past 5 years, UroGen Pharma's FCF Margin ranged from a high of -55.47% in Q4 2023 and a low of -369.91% during Q1 2021.
  • Over the past 3 years, UroGen Pharma's median FCF Margin value was -110.14% (recorded in 2024), while the average stood at -123.28%.
  • As far as peak fluctuations go, UroGen Pharma's FCF Margin skyrocketed by 57,924bps in 2021, and later crashed by 5,597bps in 2025.
  • Over the past 5 years, UroGen Pharma's FCF Margin (Quarterly) stood at -125.34% in 2021, then spiked by 504bps to -120.30% in 2022, then soared by 6,483bps to -55.47% in 2023, then tumbled by 44bps to -55.91% in 2024, then slumped by 4,399bps to -154.13% in 2025.
  • Its FCF Margin was -154.13% in Q3 2025, compared to -165.05% in Q2 2025 and -207.70% in Q1 2025.